![]() |
Market Research Report
Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development |
||||||
Published by | GBI Research | Product code | 246721 | ||||
Published | Content info | 44 Pages ![]() |
|||||
Price |
Not Available
|
Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development | ||
Published: July 10, 2012 | Content info: 44 Pages |
|
This publication has been discontinued on February 2, 2017.
GBI Research, leading business intelligence provider, has released its latest research report, entitled "Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development". Over the last decade, protein and peptide-based therapeutics have attracted more and more attention in the pharmaceutical industry. These types of molecules exert a high level of specificity on their respective molecular targets, making them highly advantageous and allowing them to be exploited therapeutically.
This report provides an overview of the targeted indications of current molecules across 22 therapeutic areas, relevant technological developments, the manufacturing processes and the current regulatory environment. In addition, an extensive analysis of the developmental pipeline for all protein and peptide-based therapeutics, excluding antibodies, across 11 therapeutic areas by phase, therapeutic area, route of administration, as well as mechanism of action and cell type/functional target is provided.
GBI Research has identified a sizable developmental pipeline for protein and peptide-based molecules in the therapeutic areas primarily targeted by these types of molecules, such as Central Nervous System (CNS), cardiovascular, immunology, musculoskeletal diseases, ophthalmology, infectious diseases, dermatology as well as metabolic, hematological, genetic, hormonal and gastrointestinal disorders. Overall, across these therapeutic areas, there are 571 molecules in the discovery, preclinical and clinical stages of development. These compounds have been identified in 953 indication-specific developmental programs, and 629 developmental programs are currently in clinical developmental.
The report also provides an overview of the top 15 licensing deals involving protein and peptide-based molecules since 2005, which are worth $6.9 billion and reflect a growing interest in licensing promising peptide and protein-based therapeutic molecules. They involve a number of major pharmaceutical companies, such as Pfizer, Sanofi, Merck & Co, Bristol-Myers Squibb and Merck Serono.
A Promising Future for Protein and Peptide Medications.
Since being recognised in the 1950's, many protein and peptide based therapeutics have been discovered. However, it is only over the last decade that developments have really drawn the attention of the pharmaceutical industry, states a new report by healthcare experts GBI Research.
According to the report*, there are currently 280 protein and peptide-based therapeutics molecules (excluding antibodies) currently being marketed for the treatment of a huge variety of diseases, ranging from cancer to HIV and hepatitis. This group of products is approved for the treatment of 283 indications across 22 therapeutic areas.
This total, however, may witness a boom in coming years, as GBI Research has identified 571 molecules in the discovery, preclinical and clinical stages of development. Even this considerable figure is likely to be an underestimate as companies do not always disclose this information. These recorded compounds exist in 953 indication-specific developmental programs, and 629 programs are currently in clinical development.
These therapy types are highly promising as they exert a high level of specificity on their respective targets, which can make them much more effective than traditional treatments. Their potential is increased by their high safety profiles and the high level of tolerance that patients exhibit to their application.
Protein and peptide therapies are not without their disadvantages, however. The size of these molecules poses substantial challenges as it can adversely affect intestinal uptake when the medication is administered orally. There are also issues regarding their half-life values and stability, with their tendency to be quickly hydrolyzed by plasma enzymes.
The cost of developing these therapeutics when compared to traditional molecules can also prove too much for some manufacturers, especially in the contemporary climate of reduced R&D spending.
Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development
This report provides an overview of the targeted indications of current molecules across 22 therapeutic areas, relevant technological developments, the manufacturing processes and the current regulatory environment
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research's team of industry experts.